Matthew Li

Matthew Li has a diverse work experience in the field of cell therapy and biomedical engineering. Matthew is currently the Director of Cell Therapy CMC at Tome Biosciences, a position they have held since May 2022. Prior to that, they worked at Vor Biopharma, starting as a Senior Scientist in Technical Operations, Process Development, and Automation from November 2019 to November 2020. Matthew then served as the Principal Scientist and Head of Cell Therapy Manufacturing Innovation from November 2020 to July 2021, followed by the role of Associate Director and Head of Cell Therapy Manufacturing Innovation from July 2021 to April 2022. Before joining Vor Biopharma, Matthew worked at Takeda as a Scientist in Cell Therapy CMC and Process Development from June 2018 to November 2019. Matthew began their career as a Postdoctoral Research Fellow in Biomedical Engineering at Massachusetts General Hospital, where they worked from July 2016 to May 2018.

Matthew Li's education history includes a Bachelor of Science (BS) degree in Bioengineering from UC San Diego. Additionally, they pursued further education at the Massachusetts Institute of Technology, where they received a Doctor of Philosophy (PhD) degree in Medical Engineering and Medical Physics. However, specific dates for their enrollment and graduation from these institutions were not provided.